2021
Building a Digital Health Risk Calculator for Older Women with Early-Stage Breast Cancer
Abujarad F, Wang S, Ulrich D, Mougalian S, Killelea B, Fraenkel L, Gross C, Evans S. Building a Digital Health Risk Calculator for Older Women with Early-Stage Breast Cancer. Lecture Notes In Computer Science 2021, 12780: 389-402. DOI: 10.1007/978-3-030-78224-5_27.Peer-Reviewed Original ResearchEarly-stage breast cancerOlder womenBreast cancerRadiation therapyTreatment therapiesEvidence-based treatment decisionsShared-decision modelRisk-benefit informationRisk calculatorRelative riskTreatment decisionsPatient healthDigital health toolsPatient comprehensionTherapyHealth toolsWomenCancerHealthPatientsCliniciansRelative risks of COVID-19 fatality between the first and second waves of the pandemic in Ontario, Canada
Hsu SH, Chang SH, Gross C, Wang SY. Relative risks of COVID-19 fatality between the first and second waves of the pandemic in Ontario, Canada. International Journal Of Infectious Diseases 2021, 109: 189-191. PMID: 34216734, PMCID: PMC8245301, DOI: 10.1016/j.ijid.2021.06.059.Peer-Reviewed Original ResearchConceptsCase fatality rateRelative riskTesting ratesPooled RR estimateCOVID-19 case fatality ratePublic health unitsCOVID-19 case fatalityCOVID-19 testingCOVID-19 testing ratesHigher testing ratesCase fatalityCOVID-19 casesCOVID-19 fatalitiesHealth unitsFatality rateSecond waveRR estimatesFirst waveCOVID-19RiskFatalitiesOntario
2017
Physician volume and discontinuation of rituximab during lymphoma treatment.
Huntington S, Long J, Hoag J, Wang R, Zeidan A, Giri S, Gore S, Ma X, Gross C, Davidoff A. Physician volume and discontinuation of rituximab during lymphoma treatment. Journal Of Clinical Oncology 2017, 35: 6593-6593. DOI: 10.1200/jco.2017.35.15_suppl.6593.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaEarly discontinuationRituximab discontinuationPhysician volumeProvider volumeEnd Results-Medicare dataB-cell non-Hodgkin lymphomaCell non-Hodgkin lymphomaCox proportional hazards modelDiscontinuation of rituximabSevere infusion reactionsRetrospective cohort studyImpact of discontinuationDays of initiationProportional hazards modelDose-dependent mannerRituximab cyclesRituximab initiationInfusion reactionsOverall survivalCohort studyPrimary outcomeSystemic treatmentLymphoma treatmentRelative risk